
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:source>The annals of thoracic surgery 113(2)</dc:source>
  <dc:rights>All rights reserved</dc:rights>
  <dc:language>eng</dc:language>
  <dc:description xml:lang="eng">BACKGROUND: The optimal antiplatelet therapy for patients with chronic kidney disease (CKD) undergoing coronary artery bypass grafting (CABG) remains unknown.
METHODS: This post hoc analysis of the Ticagrelor in Coronary Artery Bypass (TiCAB) trial examined the efficacy and safety of ticagrelor versus aspirin in patients with or without CKD. Primary endpoint was the composite of cardiovascular death, stroke, myocardial infarction or revascularization
(MACCE) at 1 year after CABG. Secondary endpoints included individual components of the primary endpoint, all-cause death, and major bleeding.
Results: CKD was present in 276 of 1,843 randomized patients (15.0%). Patients with CKD versus those without CKD had higher 1-year rates of MACCE (13.0% vs. 8.3%, HR 1.63, 95% CI 1.12-2.39, P=0.01) and major bleeding (5.6% vs. 3.1%, HR 1.84, 95% CI 1.03-3.28, P=0.04). The 1-year rate of MACCE was increased with ticagrelor versus aspirin in patients with CKD (18.2% vs. 8.9%, HR 2.15, 95% CI 1.08-4.30, P=0.03), but not in patients without CKD (8.5% vs. 8.1%, HR 1.05, 95% CI 0.74-1.49, P=0.79) (Pinteraction=0.067). There was no difference in the 1-year rate of major bleeding with ticagrelor versus aspirin in patients with CKD (6.6% vs. 4.7%, HR 1.44, 95% CI 0.52-3.97, P=0.48) and without CKD (3.3% vs. 2.9%, HR 1.14, 95% CI 0.64-2.01, P=0.65).
CONCLUSIONS: In patients with CKD and CABG, those who received ticagrelor had a higher incidence of MACCE but a similar incidence of major bleeding compared to those who received aspirin.</dc:description>
  <dc:description xml:lang="eng">Journal Pre-Proof</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:format>5698845 bytes</dc:format>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:subject xml:lang="eng">Key words: ticagrelor, aspirin, coronary artery bypass</dc:subject>
  <dc:title xml:lang="eng">Ticagrelor or aspirin after coronary artery bypass in patients with chronic kidney disease</dc:title>
  <dc:contributor>TiCAB Investigators</dc:contributor>
  <dc:identifier>https://unilib.phaidrabg.rs/o:3473</dc:identifier>
  <dc:identifier>doi:10.1016/j.athoracsur.2021.03.061</dc:identifier>
  <dc:identifier>cobiss:129074441</dc:identifier>
  <dc:identifier>ISSN: 1552-6259</dc:identifier>
  <dc:date>2022</dc:date>
  <dc:creator id="https://plus.cobiss.net/cobiss/sr/sr/conor/106341385">Sandner, Sigrid E.</dc:creator>
  <dc:creator>Schunkert, Heribert</dc:creator>
  <dc:creator>Kastrati, Adnan</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-0984-9011 https://plus.cobiss.net/cobiss/sr/sr/conor/106163721">Milojević, Milan</dc:creator>
  <dc:creator>Böning, Andreas</dc:creator>
  <dc:creator>Zimpfer, Daniel</dc:creator>
  <dc:creator>Zellmer, Stephan</dc:creator>
  <dc:creator>Wiedemann, Dominik</dc:creator>
  <dc:creator>Laufer, Günther</dc:creator>
  <dc:creator>Von Scheidt, Moritz</dc:creator>
</oai_dc:dc>
